Edwards Lifesciences (EW) Cost of Revenue (2009 - 2026)

Edwards Lifesciences' Cost of Revenue history runs 18 years deep, the most recent figure standing at $362.6 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 20.23% year-over-year to $362.6 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 23.23% YoY), while the FY2025 annual figure was $1.3 billion, up 19.39% from the prior year.
• Cost of Revenue was $362.6 million for Q1 2026 at Edwards Lifesciences, up from $343.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $362.6 million in Q1 2026 to a low of -$98.8 million in Q4 2022.
• Historically, Cost of Revenue has averaged $272.1 million across 5 years, with a median of $286.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue tumbled 131.92% in 2022, then surged 354.05% in 2023.
• A 5-year view of Cost of Revenue shows it stood at -$98.8 million in 2022, then jumped by 354.05% to $251.0 million in 2023, then climbed by 16.41% to $292.2 million in 2024, then climbed by 17.39% to $343.0 million in 2025, then rose by 5.71% to $362.6 million in 2026.
• The last three Cost of Revenue figures came in at $362.6 million (Q1 2026), $343.0 million (Q4 2025), and $345.2 million (Q3 2025), per Business Quant data.